Literature DB >> 31428141

Corrigendum to "PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors".

Elisabetta Benedetti1, Renato Galzio2, Barbara D'Angelo1, Maria Paola Cerù1, Annamaria Cimini1.   

Abstract

[This corrects the article DOI: 10.1155/2010/427401.].

Entities:  

Year:  2019        PMID: 31428141      PMCID: PMC6679841          DOI: 10.1155/2019/4309068

Source DB:  PubMed          Journal:  PPAR Res            Impact factor:   4.964


The article titled “PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors” [1] was found to contain material in Sections 1, 2, and 3 from published work and to have missing attributions and errors in citations. The articles are as follows: M. T. Heneka and G. E. Landreth, “PPARs in the brain,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1031–1045, 2007. https://doi.org/10.1016%2fj.bbalip.2007.04.016. [2] (Cited as reference [36]). Lars Tatenhorst, Eric Hahnen, and Michael T. Heneka, “Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors,” PPAR Research, vol. 2008, Article ID 204514, 9 pages, 2008. https://doi.org/10.1155/2008/204514. [3] (not cited). Markus P. Kummer and Michael T. Heneka, “PPARs in Alzheimer's Disease,” PPAR Research, vol. 2008, Article ID 403896, 8 pages, 2008. https://doi.org/10.1155/2008/403896. [4] (not cited). J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. https://doi.org/10.1016%2fj.plipres.2005.12.002. [5] (cited as reference [30]). A. Cimini, E. Benedetti, L. Cristiano et al., “Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons,” Neuroscience, vol. 130, no. 2, pp. 325–337, 2005. https://doi.org/10.1016%2fj.neuroscience.2004.09.043. [6] (cited as reference [81]).
  6 in total

Review 1.  From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.

Authors:  Jérôme N Feige; Laurent Gelman; Liliane Michalik; Béatrice Desvergne; Walter Wahli
Journal:  Prog Lipid Res       Date:  2006-01-25       Impact factor: 16.195

2.  Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons.

Authors:  A Cimini; E Benedetti; L Cristiano; P Sebastiani; M A D'Amico; B D'Angelo; S Di Loreto
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors.

Authors:  Elisabetta Benedetti; Renato Galzio; Barbara D'Angelo; Maria Paola Cerù; Annamaria Cimini
Journal:  PPAR Res       Date:  2010-03-17       Impact factor: 4.964

Review 4.  PPARs in the brain.

Authors:  Michael T Heneka; Gary E Landreth
Journal:  Biochim Biophys Acta       Date:  2007-05-10

5.  Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors.

Authors:  Lars Tatenhorst; Eric Hahnen; Michael T Heneka
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

6.  PPARs in Alzheimer's Disease.

Authors:  Markus P Kummer; Michael T Heneka
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.